Small Molecules: The Key to Intracellular Targets

Small molecules, as their name implies, are nimble, synthetic compounds consisting of 20 to 100 atoms. Their design is not just straightforward but also highly effective, making them ideal for penetrating cells where larger molecules can't reach. This remarkable ability positions small molecule therapies as critical solutions in areas that demand precise cellular access—often formulated as daily tablets.

Antibodies: A Cutting-Edge Arsenal for Targeted Therapies

At Servier, we are pioneers in recognizing the immense potential of antibodies in addressing rare cancers and neurological disorders. These proteins come in various forms—monospecific, bispecific, and antibody-drug conjugates (ADCs)—and are derived from living cells, boasting high selectivity to pinpoint disease targets.

Monoclonal Antibodies: Precision in Cancer Treatment

Monoclonal antibodies (mAbs) play a vital role in combating cancers, autoimmune conditions, and infectious diseases. They precisely bind to specific antigens, neutralizing harmful agents and empowering the immune response to act.

Revolutionizing Therapy with Bispecific Antibodies

Enter bispecific antibodies (bsAbs), engineered marvels with the capability to bind two distinct antigens simultaneously. This dual-targeting mechanism can unlock synergistic physiological responses, making them especially valuable in oncology at Servier.

Antibody-Drug Conjugates (ADCs): Direct Delivery of Power

ADCs combine a monoclonal antibody with an active drug through a specialized linker, allowing targeted cells to be penetrated and treated directly. While primarily focused on various cancers, the versatility of these therapies holds promise for treating a broader range of diseases.

Antisense Oligonucleotides: The Next Wave of Genetic Treatment

Antisense oligonucleotides (ASOs) represent a groundbreaking innovation in genetic disease treatment, targeting messenger RNA (mRNA) to impede the creation of defective proteins. By steering clear of DNA intervention, ASOs maintain a focused approach that could revolutionize care for rare and neurodegenerative diseases.

A Commitment to Innovative Solutions

At Servier, we are unwavering in our belief that these advanced technologies are pivotal in shaping the next generation of therapeutic solutions. Our research efforts are dedicated to harnessing their potential, with a special emphasis on addressing the unique needs of patients facing rare cancers and neurological challenges.